CEO Iain Foulkes describes the impact Cancer Research Horizons has already made (14 marketed medicines), which has allowed more than £600M in royalty income to be reinvested in research. He describes the structure of the organization, a new startup fund, and some notable investments.

He describes getting through the last few years and how he thinks about 2026. Plus, comments on Xenon, Madrigal, and Alkermes. Brought to you by

He discusses the rationale behind the firm's asset-centric approach and highlights Vicebio as an example of how it works. Plus, his take on the current investment environment. Coverage brought to you by

He shares his take on the capacity for pharma to do more buying, and list his favorite areas of science, which include I&I, CNS/Neurology, and modalities such as bi-specifics and tri-specifics. Coverage brought to you by

Alexandra Pygall, Naomi Leach, Kristian Shearsby, and James Gubbins discuss best practices to get the most out of your deals. Brought to you by

He expects deals to continue in 2026, and says that the bidding wars we have seen recently are likely deal specific. Coverage brought to you by

He says that investors are placing fewer, but larger bets on companies lately, and he expects a 'healthy' IPO market in 2026. Coverage brought to you by

He comments on Kymera, Apogee, Avalo, Veridian, Moonlake, Spyre, and Oruka. Coverage brought to you by

He comments on IPOs, fundraising, M&A, and China. Coverage brought to you by

He shares his thoughts on uniQure, Xenon, Alkermes, Compass Pathways, GH Research MindMed, and Dyne. Coverage brought to you by

She and her colleagues at inThought Research recently published a report summarizing the brain shuttle technology research landscape in the biotech sector.

He describes the need to target immunotherapy better by getting it right to the tumor sites, and modulating the tumor microenvironment. Coverage brought to you by

He weighs in on key issues like solid tumors, allo, and in vivo CAR-T. Plus, alpha vs beta emitters in the radiopharma space. Coverage brought to you by

He highlights Sylvester's NCI status and discusses how the institution is trying to contribute to diversity in clinical trials. Coverage brought to you by

He discusses Celcuity, Relay, Olema, and more Coverage brought to you by

Menlo Ventures Partner, and co-author of the report, Derek Xiao talks about how AI is improving the P&L of health systems and helping with staffing shortages. Medical documentation, billing and scribing are the biggest areas of adoption today, while patient engagement and the post acute relationship are emerging as next to be impacted.

MassBio CEO Kendalle Burlin O'Connell moderates a discussion with Normunity CEO Rachel Humphrey and Gallop Oncology CEO Luba Greenwood about how they are rising to today's challenges. Topics include the funding environment, motivating your team, storytelling, FDA engagement, and perseverance. Chapters Intro's – 0:52 The funding environment - 2:51 Motivating your team – 17:20 Storytelling – 28:17 Engagement with FDA – 39:51 Perseverance – 42:23 Advice for new entrepreneurs – 4

During a meeting in Boston at Portal Innovations where Women in Bio (WIB) was working on its 'Boardroom Ready' initiative, Dianne Keen-Kim (National President and Board Chair), Gina Ford (CEO), and Katherine Andersen (Board Member) discuss how WIB helps women in our industry today and its goals for the future.

The CEO of Blueprint (up to the acquisition) discusses the company's success factors, and being led to immunology by the science. Plus, why she believes an oral pill that is disease modifying, like Fulcrum is trying to develop, is strongly needed for the sickle cell patient community. Coverage brought to you by

He welcomes us to Benchtalk 2025, which had more than 800 scientists register this year, and describes how AI and other computational advances are allowing scientists to focus on increasing the speed and reducing the cost of R&D. Coverage brought to you by